Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 58Neoplasms 51Lung Neoplasms 33Colorectal Neoplasms 28Carcinoma, Non-Small-Cell Lung 25Prostatic Neoplasms 22Melanoma 19Pancreatic Neoplasms 17Ovarian Neoplasms 16Uterine Cervical Neoplasms 14Sarcoma 12Multiple Myeloma 12Lymphoma 11Glioma 11Glioblastoma 11Neoplasm Metastasis 10Leukemia, Myeloid, Acute 10Colonic Neoplasms 10Neoplastic Cells, Circulating 9Hematologic Neoplasms 9Lymphoma, Follicular 8Head and Neck Neoplasms 8Carcinoma, Hepatocellular 8Leukemia 7Endometrial Neoplasms 7Brain Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Papillomavirus Infections 6Myelodysplastic Syndromes 6Disease 6

Interventions

cabozantinib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × High Grade Neuroendocrine Neoplasms × Blood Specimen Collection × Clear all
NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡